Author: admin
This webinar will be hosted live and available on-demandWednesday, April 8, 202611:00 AM – 3:30 PM ETNew approach methodologies (NAMs) can generate human-relevant data that complements traditional approaches. As such, in vitro NAM technologies, such as organoids, organ-on-a-chip systems, and other in vitro human tissue models, are being increasingly used to gain human-relevant insights throughout drug discovery processes. These systems offer insights into biological processes and therapeutic interactions, giving scientists a stronger base of evidence to guide decision-making.In this half-day virtual summit, brought to you by STEMCELL Technologies, invited scientists and industry professionals will discuss the real-world impact and evolving…
2026 kicked off with a stream of AI platform deals across pharma, signaling a cultural shift away from single-asset bets and toward investment in AI infrastructure for broad discovery. The collaborations between AI start-ups, Chai Discovery, Noetik, and Boltz, and pharma giants, Eli Lilly, GSK, and Pfizer, respectively, will implement AI platforms across diverse applications, including biologics design, cancer clinical outcome prediction, and small molecule drug discovery. “If 2025 was the year of breakthrough research, we believe 2026 will become the year of deployment,” said Jack Dent, co-founder at Chai. Launched in 2024, the AI-driven biologics company aims to develop medicines against targets that have previously been undruggable. Chai closed out 2025 with…
Glioblastoma brain cancer. Coloured computed tomography (CT) scan of a section through the brain of an 84-year-old female patient with glioblastoma (dark, top). Glioblastoma is the most aggressive form of brain cancer. Treatment involves surgery, after which chemotherapy and radiation therapy are used. However, the cancer usually reoccurs despite treatment and the most common length of survival after diagnosis is 12-15 months. Without treatment, survival is typically 3 months. Glioblastoma (GBM) remains one of the most aggressive and lethal brain cancers, in large part because of its uncanny ability to infiltrate the brain far beyond the visible tumor mass. Even…
At the interface of engineering and biology, this postdoc builds platforms for next-generation immunotherapies.Image credit:Charuchandra Kinjawadekar, ©iStock.com, OlemediaAmeya Dravid is a postdoctoral researcher in Ankur Singh’s lab at Georgia Tech. In this postdoc portrait article, he discusses his work in B cell and plasma cell immunoengineering.Q | What’s your research background? My current work on hydrogel-based delivery platforms builds upon my PhD at the Indian Institute of Science (IISc), where I investigated liposomal nanoparticles for osteoarthritis, uniting biomaterials innovation with immune modulation for long-term therapies.Q | How did you first get interested in science? My first spark for science came…
There’s a quiet truth we keep coming back to at BiotiQuest: health isn’t built in grand gestures. It’s shaped slowly and consistently by the small choices we make every day. What we eat. What we clean with. What we breathe in, wash off, filter out, or unknowingly invite into our homes and bodies. That understanding is what inspired the our new Community Learning Lab, formerly known as The Sugar Shift Challenge. This is more than a place to talk about probiotics or gut health—though yes, we’ll absolutely still be talking about the gut and sugar metabolism. It’s a shared space…
Credit: Storman / iStock / Getty Images Plus Researchers at Helmholtz Munich and the Technical University of Munich (TUM) have developed a new imaging technology that can noninvasively capture three-dimensional information from capillaries to detect early signs of heart disease. The system is called fast raster-scan optoacoustic mesoscopy (fast-RSOM) and is designed to visualize and quantify through the skin microvascular endothelial dysfunction (MiVED), a biomarker that often precedes dysfunction in larger arteries. The development of this new technology is published in the journal Light Science & Applications. “With fast-RSOM, we can, for the first time, noninvasively assess endothelial dysfunction at…
SPT Labtech, a global leader in the design and development of laboratory automation and liquid handling solutions, today announced the availability of validated automated workflows for Twist Bioscience’s next-generation sequencing (NGS) library preparation kits on its firefly® liquid handling platform. Developed through a collaboration with Twist Bioscience, the workflows are designed to support higher-throughput, more reproducible NGS library preparation and are accessible directly through the firefly cloud.Development of these workflows reflects growing demand across genomics research and core facilities for standardized automated protocols that improve consistency while reducing hands-on time as sequencing volumes continue to increase. The initial validate automated…
Credit: STEVE GSCHMEISSNER/SCIENCE PHOTO LIBRARY / Getty Images Having a larger body size just before entering puberty critically influences a woman’s risk of breast cancer during her most fertile years, research suggests. The genome-wide association study, in Science Advances, highlights the importance of early life stages as important windows of susceptibility for disease. The findings revealed that that prepubertal adiposity, occurring just before puberty and often considered between the ages of nine and 12 years, had an important impact in lowering breast cancer risk among women aged less than 40 years. It mostly accounted for the benefits of body mass…
In this episode, we delve into the fascinating world of gut health with microbiome researcher and health innovator, Martha Carlin. As the founder of The BioCollective, Martha’s dedicated her career to understanding how gut health, blood sugar balance, and environmental exposures influence chronic diseases.
Identifying the root of any given disease is often the first step in developing effective therapies. Neurodegenerative diseases are notoriously difficult to study and treat. Conditions like multiple sclerosis—an autoimmune disease characterized by myelin degradation—are especially challenging to test in vivo. A team at Johns Hopkins Medicine led by Dwight Bergles, PhD, has focused their work on myelin development using oligodendrocytes. While oligodendrocyte precursor (OPCs) are the largest population of progenitor cells in the adult brain, their differentiation mechanisms are not well understood. “OPCs are fascinating because they enable one of the longest developmental programs in the brain,” Bergles told…